BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:BSX • US1011371077

65.6 EUR
-0.4 (-0.61%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Overall BSX gets a fundamental rating of 5 out of 10. We evaluated BSX against 63 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of BSX get a neutral evaluation. Nothing too spectacular is happening here. BSX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year BSX was profitable.
  • In the past year BSX had a positive cash flow from operations.
  • BSX had positive earnings in 4 of the past 5 years.
  • Of the past 5 years BSX 4 years had a positive operating cash flow.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • BSX's Return On Assets of 6.54% is fine compared to the rest of the industry. BSX outperforms 75.00% of its industry peers.
  • BSX has a Return On Equity of 11.93%. This is in the better half of the industry: BSX outperforms 72.06% of its industry peers.
  • With a decent Return On Invested Capital value of 8.09%, BSX is doing good in the industry, outperforming 70.59% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for BSX is below the industry average of 9.98%.
  • The last Return On Invested Capital (8.09%) for BSX is above the 3 year average (6.59%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROIC 8.09%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

  • With an excellent Profit Margin value of 14.42%, BSX belongs to the best of the industry, outperforming 83.82% of the companies in the same industry.
  • BSX's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 19.40%, BSX belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
  • BSX's Operating Margin has been stable in the last couple of years.
  • Looking at the Gross Margin, with a value of 68.57%, BSX is in the better half of the industry, outperforming 77.94% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
Industry RankSector Rank
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
  • There is no outstanding debt for BSX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • BSX has an Altman-Z score of 4.54. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.54, BSX is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
  • The Debt to FCF ratio of BSX is 3.03, which is a good value as it means it would take BSX, 3.03 years of fcf income to pay off all of its debts.
  • BSX's Debt to FCF ratio of 3.03 is fine compared to the rest of the industry. BSX outperforms 75.00% of its industry peers.
  • BSX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
  • BSX has a Debt to Equity ratio (0.48) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Altman-Z 4.54
ROIC/WACC0.83
WACC9.77%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

  • BSX has a Current Ratio of 1.51. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of BSX (1.51) is comparable to the rest of the industry.
  • BSX has a Quick Ratio of 1.51. This is a bad value and indicates that BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BSX has a Quick ratio (0.96) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 0.96
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.51% over the past year.
  • The Earnings Per Share has been growing by 26.01% on average over the past years. This is a very strong growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.9%

3.2 Future

  • Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.63% on average per year.
  • Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 10.66% on average per year.
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.63%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.66%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 25.33, which means the current valuation is very expensive for BSX.
  • Compared to the rest of the industry, the Price/Earnings ratio of BSX indicates a somewhat cheap valuation: BSX is cheaper than 63.24% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.93. BSX is around the same levels.
  • With a Price/Forward Earnings ratio of 22.09, BSX is valued on the expensive side.
  • The rest of the industry has a similar Price/Forward Earnings ratio as BSX.
  • BSX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.77, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 25.33
Fwd PE 22.09
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit more expensive than the industry average as 63.24% of the companies are valued more cheaply.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as BSX.
Industry RankSector Rank
P/FCF 30
EV/EBITDA 24.49
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • BSX has a very decent profitability rating, which may justify a higher PE ratio.
  • BSX's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.71
PEG (5Y)0.97
EPS Next 2Y14.13%
EPS Next 3Y13.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BSX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BOSTON SCIENTIFIC CORP

FRA:BSX (2/6/2026, 7:00:00 PM)

65.6

-0.4 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-21
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap97.25B
Revenue(TTM)N/A
Net Income(TTM)2.79B
Analysts85.5
Price Target107.92 (64.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-1.07%
PT rev (3m)-2.12%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0%
EPS NY rev (3m)0.03%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.04%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE 25.33
Fwd PE 22.09
P/S 5.93
P/FCF 30
P/OCF 24.8
P/B 4.9
P/tB N/A
EV/EBITDA 24.49
EPS(TTM)2.59
EY3.95%
EPS(NY)2.97
Fwd EY4.53%
FCF(TTM)2.19
FCFY3.33%
OCF(TTM)2.65
OCFY4.03%
SpS11.07
BVpS13.38
TBVpS-1.13
PEG (NY)1.71
PEG (5Y)0.97
Graham Number27.92
Profitability
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROCE 10.04%
ROIC 8.09%
ROICexc 8.38%
ROICexgc 28.19%
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
FCFM 19.76%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Debt/EBITDA 2.18
Cap/Depr 59.36%
Cap/Sales 4.14%
Interest Coverage 250
Cash Conversion 90.6%
Profit Quality 136.98%
Current Ratio 1.51
Quick Ratio 0.96
Altman-Z 4.54
F-Score6
WACC9.77%
ROIC/WACC0.83
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.9%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.66%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.52%
EBIT Next 3Y20.65%
EBIT Next 5Y17.42%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%

BOSTON SCIENTIFIC CORP / BSX.DE FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 4 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Fairly Valued.


How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 25.33 and the Price/Book (PB) ratio is 4.9.


Can you provide the expected EPS growth for BSX stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 14.83% in the next year.